NCT04677777 - Safety Study of PP-007 in Subjects With Acute Ischemic Stroke | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 24, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

February 28, 2025

Conditions

Acute Ischemic Stroke

Interventions

BIOLOGICAL

PP-007 (Two doses administered 24±6 hours apart) + SOC (IVT or MT or IVT+MT)

PP-007 is PEGylated carboxyhemoglobin. Eligible patients will receive two doses of PP-007 (at least 24 hours apart) to evaluate extended drug exposure along with MT and/or IVT (individually or together) as SOC to evaluate safety in AIS patients.

Trial Locations (8)

15213

NOT_YET_RECRUITING

UPMC Stroke Institute, Pittsburgh

30303

RECRUITING

Emory University School of Medicine, Atlanta

32207

RECRUITING

Baptist Health Research Institute, Jacksonville

33176

RECRUITING

Baptist Health Miami Cardiac & Vascular Institute (MCVI), Miami

43608

RECRUITING

Mercy Health - St. Vincent Medical Center, Toledo

64111

RECRUITING

Saint Luke's Hospital, Kansas City

73104

RECRUITING

University of Oklahoma Health Sciences Center, Oklahoma City

97239

RECRUITING

Oregon Stroke Center at Oregon Health & Science University (OHSU), Portland